Dec 03,2018

Impact of a digital health intervention on asthma resource utilization

This quality improvement project assessed the benefit of these interventions (Propeller Health) on asthma-related healthcare utilizations, including hospitalizations, emergency department (ED) utilization and outpatient visits. In 224 study patients, the number of asthma-related ED visits and combined ED and hospitalization events 365 days pre- to 365 days post-enrollment to the intervention significantly decreased from 11.6 to 5.4 visits (p < 0.05) and 13.4 to 5.8 events (p < 0.05) per 100 patient-years, respectively. This digital health intervention was successfully incorporated into routine clinical practice and was associated with lower rates of asthma-related hospitalizations and ED visits.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 16,2017

Propeller Health and Express Scripts Partnership Offers Innovative Digital Respiratory Care to Improve Health for People with Asthma or COPD

Today, Propeller Health and Express Scripts announced a strategic partnership to provide Propeller’s FDA-cleared digital solution to Express Scripts members using inhaler sensors and a mobile app to manage asthma or COPD. This collaboration is the largest respiratory digital health deployment with a pharmacy benefit manager to date. Express Scripts members who participated in an early-stage version of this solution saw an 80 percent reduction in average rescue events per day and a significant improvement in adherence to their asthma controller medication.

COLLABORATION PARTNERSHIP

#institution

#pdt

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 16,2017

Five digital health trends investors are watching in 2017

Skip Fleshman is a partner at Asset Management Ventures who has invested in companies such as Proteus Digital Health, WellDoc, HealthTap, Evidation Health, Reify Health, Lark and Welkin. He shares his insights and opnions ont he digital health trends including digital therapeutics. He pointed interesting companies in this sector target diabetes prevention (Omada Health), Type 2 diabetes (WellDoc), mental health (Pear Therapeutics) and respiratory illness (Propeller Health).

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Jan 14,2016

Effectiveness of Population Health Management Using the Propeller Health Asthma Platform: A Randomized Clinical Trial

Telemonitoring of short-acting b-agonist (SABA) focuses on patterns of use and may allow more timely action to avert exacerbations. Studies assessing this approach are lacking. This pragmatic controlled study was designed to measure real-world effectiveness of the Propeller Health Asthma Platform to reduce use of SABA and improve asthma control. A total of 495 patients were enrolled in parallel arms (1:1) for 12 months of monitoring SABA use. Intervention group (IG) patients received access to and feedback from the Propeller Health system. Routine care (RC) patients were outfitted with sensors but did not receive feedback. Compared with RC, the study arm monitoring SABA use with the Propeller Health system significantly decreased SABA use and improved Asthma Control Test-ACT scores

CLINICAL STUDY

#telehealth

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 23,2016

Propeller Health and Boehringer Ingelheim Announce New Partnership Focused on Improving Adherence and Care Management for People Living with COPD and Asthma

Propeller Health, the leading digital health solution for respiratory medicine, and Boehringer Ingelheim Pharmaceuticals Inc., a global pharmaceutical company and leading provider of inhaled medications for serious respiratory diseases, today announced a commercial partnership. Under the terms of the partnership, people living with COPD and asthma, who are being treated with a Boehringer Ingelheim prescription medication approved for use in the company’s RESPIMAT® inhaler, will have the opportunity to enroll at select U.S. health systems in a new program that is designed to determine how Propeller’s novel health technology tool for the RESPIMAT inhaler impacts adherence rates and patient engagement.

COLLABORATION PARTNERSHIP

#r&d

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 13,2014

Q&A with Propeller Health Advisor Dr. David Mannino

Propeller Health Advisor Dr. David Mannino shared his insights and journey in the Propeller Health

View Analyst & Ambassador Comments
Go to original news
Jan 28,2014

January Stat: Percentage of People with Asthma Action Plans Increased 56% After Propeller

Only 20% of Propeller users had an asthma action plan when they enrolled, but that percentage increased by 56% once they start using Propeller and sharing the data with their care team.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Feb 11,2014

February Stat: Over 85% of Propeller Users Welcome Our Messages

About 10% of Propeller users receive an email, text, smartphone alert or phone call about their – or their loved one’s – asthma and rescue inhaler usage. In a recent survey, over 85% of our users said that the amount of communication they received from Propeller was either “just right” or they would like to hear from us even more.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 19,2014

New Propeller Provider Dashboard Saves Time and Clicks

Propeller Health is excited to announce a new dashboard for health care providers is now live! The changes are direct result of the providers' feedback.

PRODUCT

#software

#rpm

View Analyst & Ambassador Comments
Go to original news
Sep 04,2014

Propeller Health Raises $14.5 Million Series B Financing Led by Safeguard Scientifics

Propeller Health, the FDA-cleared digital health solution for chronic respiratory disease, today announced that it raised $14.5 million in Series B financing, led by Safeguard Scientifics (NYSE:SFE) with participation from Series A investor The Social+Capital Partnership. Propeller Health will use the funding to accelerate product development, strategic alliances, client services, sales and marketing.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to RESPIRATORY